In marking National Kidney Month, this episode features an interview with Robert Perkins, MD, Vice President, US Medical Affairs (Renal) at Bayer who spoke about kidney health and diabetes-inflicted chronic kidney disease.
National Kidney Month is observed every March in the US to raise awareness about kidney health and promote preventive action. It aims to educate the public about the importance of kidneys to overall health and the risk factors for kidney disease, a major one being diabetes.
At Bayer, Dr. Perkins is the strategic lead for a team of 8 HQ-based medical directors and a 40-member field medical team. He is responsible for evidence portfolio across two therapeutic indications, chronic kidney disease and heart failure, encompassing seven active trials and studies and more than 3,000 US patients. Dr. Perkins has also led the development and implementation of innovative digital educational outreach campaigns for primary care physicians. In previous roles, Dr. Perkins helped build and develop medical teams at Novartis and AstraZeneca.
Vice President
US Medical Affairs, Renal
Bayer
Last year, the American Diabetes Association (ADA) updated their standards of care guidelines for 2024, which outline strategies for diagnosing and treating diabetes (both type 1 and type 2) and outline methods of preventing and delaying type 2 diabetes as well as associated comorbidities like cardiovascular disease and chronic kidney disease.
Tune into the episode to hear Dr. Perkins’ insights about current advancements and challenges in tackling chronic kidney disease, the updated ADA guidelines and how a comprehensive approach to treating diabetes is necessary for reducing the risk of kidney complications.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN